S100A8/A9 and Innate Immunity in Liver Disease
Research type
Research Study
Full title
The Interaction of the S100A8/A9 Protein with the Innate Immune System in the Immunopathology of Acute and Chronic Liver Disease
IRAS ID
285573
Contact name
Arjuna Singanayagam
Contact email
Sponsor organisation
St. George's University of London
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
This is a prospective observational study of human participants with liver disease investigating the concentration and function of an immune protein called S100A8/A9 (calprotectin) at different stages of the disease and in different organ systems (e.g. blood, urine, abdominal cavity, stool, lungs, liver) and how it may relate to clinical outcomes (development of infection, organ failure, death or need for liver transplant). S100A8/A9 is produced by damaged cells and myeloid cells (neutrophils, monocyte and macrophages) and has been evaluated in other disease such as sepsis and rheumatoid arthritis where it promotes inflammation and predicts outcome. This has not been fully been evaluated in liver diseases. The aim would be to identify whether it could be a target for drug therapy in order to improve the prognosis of unwell patients with advanced liver disease.
REC name
London - South East Research Ethics Committee
REC reference
21/LO/0519
Date of REC Opinion
25 Aug 2021
REC opinion
Further Information Favourable Opinion